N-stearoyl-dopamine: a dopamine derivative [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 10025103 |
| CHEMBL ID | 257212 |
| CHEBI ID | 186909 |
| SCHEMBL ID | 883453 |
| MeSH ID | M0483630 |
| Synonym |
|---|
| n-[2-(3,4-dihydroxyphenyl)ethyl]octadecanamide |
| NCGC00092336-01 |
| CHEMBL257212 |
| n-(3,4-dihydroxyphenethyl)stearamide |
| n-stearoyl dopamine |
| CHEBI:186909 |
| 105955-10-0 |
| stearda |
| SCHEMBL883453 |
| Z221503626 |
| n-stearoyldopamine |
| AKOS024456988 |
| DTXSID50434391 |
| J-001506 |
| n-stearoyl-dopamine |
| SKN6T3V4BB , |
| n-(2-(3,4-dihydroxyphenyl)ethyl)-octadecanamide |
| unii-skn6t3v4bb |
| CS-0028824 |
| PD070686 |
| Class | Description |
|---|---|
| carboxamide | An amide of a carboxylic acid, having the structure RC(=O)NR2. The term is used as a suffix in systematic name formation to denote the -C(=O)NH2 group including its carbon atom. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 0.6310 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID326218 | Inhibition of Bacillus anthracis lethal factor up to 100 uM by FRET assay | 2008 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 18, Issue:7 | Inhibitors of anthrax lethal factor based upon N-oleoyldopamine. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.63) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||